IDEXX Laboratories, Inc.
HealthcareNASDAQ:IDXX · NASDAQ Global Select
+$1.46 today
Vol 0.23M · Avg 0.58M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
66.0%
avg -377.4%
ROIC
40.3%
avg 31.0%
ROA
31.6%
avg 23.3%
Analysis
ROE is currently the strongest return metric at 66.0% versus its period average of -377.4%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jonathan J. Mazelsky | Executive Chairman | $3.78M | — | 65 | $0.00 | <0.01% |
Michael Erickson | President, Chief Executive Officer & Director | $3.78M | — | 52 | $14,229.35 | 0.02% |
Michael J. Lane | Executive Vice President and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | $1.32M | — | 58 | $14,229.35 | 0.02% |
Nimrata Khatra Hunt | Advisor | $1.25M | — | 58 | $18,140.94 | 0.02% |
Martin Smith | Executive Vice President of Global Operations and R&D | $1.24M | — | 58 | $2,458.66 | <0.01% |
Andrew Emerson | Executive Vice President, Chief Financial Officer & Treasurer | $1.13M | — | 43 | $4,345.44 | <0.01% |
Sharon E. Underberg | Executive Vice President, General Counsel, & Corporate Secretary | $881,053.00 | — | 65 | $0.00 | <0.01% |
Amit Gupta | Senior VP, Chief Digital & Information Officer | — | — | — | — | — |
Eric Tracy | Senior Vice President Customer Experience | — | — | — | — | — |
Bob Asmann | Senior Vice President of Global Operations | — | — | — | — | — |
Daniel Janson | Senior VP & GM of Global Reference Laboratories | — | — | — | $525.00 | <0.01% |
George J. Fennell | Executive Vice President of Global CAG Commercial | — | — | 57 | $10,433.00 | 0.01% |
Jeffrey Carr | Senior Vice President, GM and Head of Product for Global Reference Labs & IBA | — | — | — | — | — |
Michael Johnson | Executive Vice President & Chief Human Resources Officer | — | — | 48 | $14,229.35 | 0.02% |
Michael Schreck | Executive VP & GM of Veterinary Software and Services, Corporate Accounts and Customer Experience | — | — | 58 | $14,229.35 | 0.02% |
Murthy Yerramilli | Senior VP of Assay and Instrument Research & Development | — | — | — | — | — |
Julie Godon | Senior Vice President & Global Marketing Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
23
$22.53M
Net Sentiment
$22.53M
Net selling
Most Active
MAZELSKY JONATHAN JAY
13 transactions
1–10 of 23
Analysis
Insiders reported 0 buys worth $0.00 and 23 sells worth $22.53M over the last 12 months. That adds up to net selling of $22.53M. MAZELSKY JONATHAN JAY was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +8.8% | +18.5% (15yr)6 analysts |
| Revenue | N/A | N/A | +7.4% | +10.3% (15yr)5 analysts |
| Net Income | N/A | N/A | +2.5% | +17.3% (15yr)5 analysts |
| EBIT | N/A | N/A | +4.5% | +13.7% (15yr)5 analysts |
Analysis
Recent growth has been strongest in EPS at +8.8% over three years. Forward estimates point to EPS at +18.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
argenx SE
NASDAQ:ARGX
$55.60B
Cencora, Inc.
NYSE:COR
$54.90B
Becton, Dickinson and Company
NYSE:BDX
$52.82B
Cardinal Health, Inc.
NYSE:CAH
$52.34B
Edwards Lifesciences Corporation
NYSE:EW
$48.80B
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
$37.89B
Agilent Technologies, Inc.
NYSE:A
$36.54B
Zoetis Inc.
NYSE:ZTS
$33.66B
IQVIA Holdings Inc.
NYSE:IQV
$29.85B
Veeva Systems Inc.
NYSE:VEEV
$25.83B
Who manages IDXX?
IDEXX Laboratories, Inc. (IDXX) lists 17 active executives. The top listed executive is Jonathan J. Mazelsky, Executive Chairman.
Are IDXX insiders buying or selling?
Recent insider activity shows net selling of $4.59M.
Explore More
Continue the stock analysis
Jump to another research area for this company.